R&D News | pharmaphorum

News

GSK abandons cough drug added in $2bn Bellus deal

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.

News

Radiopharma firm AdvanCell raises $315m, and other financing...

This week's round-up of private financings in the biotech arena features AdvanCell, alongside Draig, Drug Farm, MindRank AI, and Alchemab.

News

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.

News

Two more biotechs, Attovia and Braveheart, join the IPO line

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.

News

Biogen, Ionis trumpet Alzheimer's data, but shares dip

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

GSK abandons cough drug added in $2bn Bellus deal

Radiopharma firm AdvanCell raises $315m, and other financing...

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

Two more biotechs, Attovia and Braveheart, join the IPO line

Biogen, Ionis trumpet Alzheimer's data, but shares dip

New biotech Avere plots listing via NextCure merger

Enhertu OK ends 10-year EU gap in frontline breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks